Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 14, 2026; 32(42): 119693
Published online Nov 14, 2026. doi: 10.3748/wjg.119693
Published online Nov 14, 2026. doi: 10.3748/wjg.119693
Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis
Antonio M Caballero-Mateos, Department of Internal Medicine, Gastroenterology Section, Santa Ana Hospital, Motril 18600, Spain
Antonio M Caballero-Mateos, Precision Medicine Unit, Institute of Biosanitary Research, Granada 18012, Spain
Teresa Valdés-Delgado, Department of Gastroenterology, Virgen Macarena University Hospital, Seville 41009, Spain
Raúl Olmedo-Martín, Patricia Romero-Cara, Department of Gastroenterology, Hospital Regional Universitario de Malaga, Malaga 29010, Spain
María del Mar Martín-Rodríguez, Division of Digestive Diseases, Inflammatory Bowel Diseases Unit, Virgen de las Nieves University Hospital, Granada 18014, Spain
Ana Lancho Muñoz, Department of Gastroenterology, Virgen de las Nieves University Hospital, Granada 18012, Spain
Melody Moreno-Barrueco, Department of Gastroenterology, San Cecilio University Hospital, Granada 18012, Spain
Raúl Gijón-Villanova, Department of Gastroenterology, Poniente Hospital, El Ejido 04700, Spain
Nuria Fernández-Moreno, Department of Gastroenterology, Costa del Sol Hospital, Marbella 29603, Spain
Francisco J Rodríguez-González, Department of Gastroenterology, Virgen de la Victoria University Hospital, Malaga 29101, Spain
Álvaro Hernández-Martínez, Division of Digestive Diseases, Inflammatory Bowel Diseases Unit, Hospital Universitario Torrecárdenas, Almeria 04009, Spain
Ana María Trapero-Martínez, Department of Gastroenterology, Jaén University Hospital, Jaén 23007, Spain
Ana Bejarano-García, Department of Gastroenterology, Juan Ramón Jiménez Hospital, Huelva 21005, Spain
José Manuel Benitez Cantero, Department of Gastroenterology, Reina Sofia University Hospital, Cordoba 14004, Spain
Francisco J Mata-Perdigón, Department of Gastroenterology, Puerto Real Hospital, Puerto Real 11510, Spain
Antonia Sáez-Díaz, Department of Statistics, Axioma Comunicaciones, Sevilla 41006, Spain
Federico Argüelles-Arias, Division of Digestive Diseases, Inflammatory Bowel Diseases Unit, Virgen Macarena University Hospital, Sevilla 41009, Spain
Author contributions: Caballero-Mateos AM, Valdés-Delgado T, and Argüelles-Arias F contributed to study conception and design; Caballero-Mateos AM, Romero-Cara P, Lancho Muñoz A, Martín-Rodríguez MDM, Moreno-Barrueco M, Gijón-Villanova R, Fernández-Moreno N, Rodríguez-González FJ, Hernández-Martínez Á, Trapero-Martínez AM, Olmedo-Martín R, Bejarano-García A, Mata-Perdigón FJ, Benitez Cantero JM, and Sáez-Díaz contributed to acquisition and collection; Argüelles-Arias F and Sáez-Díaz A contributed to statistical analysis and data interpretation; Valdés-Delgado T and Caballero-Mateos AM contributed to manuscript drafting; Valdés-Delgado T, Rodríguez-González FJ, Olmedo-Martín R, and Argüelles-Arias F contributed to critical revision of the manuscript for important intellectual content; Caballero-Mateos AM and Argüelles-Arias F did supervision and final approval; Valdés-Delgado T, Argüelles-Arias F, and Caballero-Mateos AM are guarantor of article; and all authors have read and approved the final version.
Institutional review board statement: The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, with protocol approval obtained from the Ethics Committee of Granada, Spain, No. 1968-N-23.
Informed consent statement: All patients provided written informed consent before inclusion in the study.
Conflict-of-interest statement: Caballero-Mateos AM has received fees for lectures, consultancy work, or research support from Lilly, Abbvie, Johnson and Johnson, Takeda, Pfizer, Alfasigma, Ferring, Farmasierra, Kern, and Faesfarma. Valdés-Delgado T has served as speaker, consultant, and advisory member for, or has received research funding from Janssen, Tillotts Pharma, and Galapagos. Olmedo-Martín R has received payments as fees-for-service and advisory work from MSD, Abbvie, Takeda, Ferring, Faes Farma, and Janssen. Hernández-Martínez Á has received payments as fees-for-service, participation in scientific meetings, and funding for attendance from Abbvie, Ferring, Janssen, MSD, Pfizer, Sandoz, and Takeda. Argüelles-Arias F has served as a speaker for Abbvie, Johnson and Johnson, Takeda, Roche, Gilead, Pfizer and Alfasigma and has served as an advisor for Roche, Gilead, Abbvie, Alfasigma and Takeda.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: The data that support the findings of this study are available from the authors on reasonable request.
Corresponding author: Teresa Valdés-Delgado, Department of Gastroenterology, Virgen Macarena University Hospital, Dr. Fedriani, Seville 41009, Spain. teresavaldes4@hotmail.com
Received: February 3, 2026
Revised: February 27, 2026
Accepted: April 13, 2026
Published online: November 14, 2026
Processing time: 231 Days and 7.9 Hours
Revised: February 27, 2026
Accepted: April 13, 2026
Published online: November 14, 2026
Processing time: 231 Days and 7.9 Hours
Core Tip
Core Tip: Risankizumab, a selective interleukin-23p19 inhibitor, emerges as a promising therapeutic option for patients with multirefractory Crohn’s disease. This multicenter real-world study of 205 patients demonstrates that risankizumab rapidly achieves clinical remission (49% at week 12) and maintains steroid-free remission in over 40% of patients throughout one-year follow-up. The excellent safety profile and high treatment persistence (> 90%) establish interleukin-23 blockade as a key strategy for patients with limited biologic alternatives in routine clinical practice.